Live Breaking News & Updates on Trial Eighth Edition

Share this article
Share this article
ResearchAndMarkets.com s offering.
The sales of hydroxychloroquine in the Chinese market have been rising steadily, from CNY 258 million in 2016 to CNY 343 million in 2020, with a CAGR of 7.34% from 2016 to 2020. In 2020, China s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.
Hydroxychloroquine is commonly used to prevent and treat malaria. The pharmacokinetics of hydroxychloroquine is similar to that of chloroquine. It can be rapidly absorbed in the gastrointestinal tract and excreted in the kidneys. Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.
The market demand for hydroxychloroquine in China is relatively large. There are two companies approved for manufacturing hydroxychloroquine, namely Shanghai Zhongxi Pharmaceutical Co., Ltd. and Sanofi-aventis Ireland Ltd. Shanghai Zhongxi Pharmaceutical Co., ....

Hydroxychloroquine Fenle , Laura Wood , Hydroxychloroquine Plaquenil , National Health Commission Of China , Office Hours Call , Shanghai Zhongxi Pharmaceutical Co Ltd , World Health Organization , Drug Administration , Development Of Hydroxychloroquine , E St Office Hours Call , Shanghai Municipal Health Commission , Development Of China Hydroxychloroquine Market , Sanofi Aventis Ireland Ltd , Hydroxychloroquine Market , Sanofi Aventis Ireland , Shanghai Zhongxi Pharmaceutical , Emergency Use Authorization , Hydroxychloroquine Sulfate , Treatment Plan , Trial Eighth Edition , National Health Commission , Topics Covered , Dosage Form , Major Hydroxychloroquine Manufacturers , Market Share , Major Hydroxychloroquine ,